Search research articles
Contact Us
Filters
Showing results (201-210 of 278) with videos related to
Page
of 28
Sort By:
Plos One
|
August 31, 2011
H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model
M Keith Howard, Nicolas Sabarth, Helga Savidis-Dacho, et al.
Journal of the Endocrine Society
|
February 2, 2026
Bone Age Delay in X-linked Hypophosphatemia
Julio Soto, Rucha Anant Patki, Lauren J Ehrlich, et al.
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity
|
October 7, 2004
Measurement of abdominal fat by CT compared to waist circumference and BMI in explaining the presence of coronary calcium
J K Snell-Bergeon, J E Hokanson, G L Kinney, et al.
Vaccine
|
August 17, 2011
Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme
Alexandra Loew-Baselli, Eva Maria Poellabauer, Borislava G Pavlova, et al.
Seminars in Thrombosis and Hemostasis
|
July 16, 2010
Preclinical testing of human recombinant von Willebrand factor: ADAMTS13 cleavage capacity in animals as criterion for species suitability
Eva-Maria Muchitsch, Barbara Dietrich, Hanspeter Rottensteiner, et al.
Antimicrobial Agents and Chemotherapy
|
November 2, 2016
Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects
Didier Scherrer, Regine Rouzier, Marine Cardona, et al.
Journal of Thrombosis and Haemostasis : JTH
|
May 9, 2009
Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor
K Varadi, H Rottensteiner, S Vejda, et al.
The Journal of Allergy and Clinical Immunology. Global
|
October 2, 2023
ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial
Pedro Giavina-Bianchi, Eric Cua, Karine Risso, et al.
Vaccine
|
May 11, 2010
Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccine
Eva Maria Pöllabauer, Sandor Fritsch, Borislava G Pavlova, et al.
Antibiotics & Chemotherapy (Northfield, Ill.)
|
February 19, 2014
6-Diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance. I. Biologic studies
G L COFFEY, J EHRLICH, M W FISHER, et al.
Page
of 28
Search research articles
Search
Showing results (201-210 of 278) with videos related to
Sort By:
Page
of 28
Plos One
|
August 31, 2011
H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model
M Keith Howard, Nicolas Sabarth, Helga Savidis-Dacho, et al.
Journal of the Endocrine Society
|
February 2, 2026
Bone Age Delay in X-linked Hypophosphatemia
Julio Soto, Rucha Anant Patki, Lauren J Ehrlich, et al.
International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity
|
October 7, 2004
Measurement of abdominal fat by CT compared to waist circumference and BMI in explaining the presence of coronary calcium
J K Snell-Bergeon, J E Hokanson, G L Kinney, et al.
Vaccine
|
August 17, 2011
Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme
Alexandra Loew-Baselli, Eva Maria Poellabauer, Borislava G Pavlova, et al.
Seminars in Thrombosis and Hemostasis
|
July 16, 2010
Preclinical testing of human recombinant von Willebrand factor: ADAMTS13 cleavage capacity in animals as criterion for species suitability
Eva-Maria Muchitsch, Barbara Dietrich, Hanspeter Rottensteiner, et al.
Antimicrobial Agents and Chemotherapy
|
November 2, 2016
Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects
Didier Scherrer, Regine Rouzier, Marine Cardona, et al.
Journal of Thrombosis and Haemostasis : JTH
|
May 9, 2009
Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor
K Varadi, H Rottensteiner, S Vejda, et al.
The Journal of Allergy and Clinical Immunology. Global
|
October 2, 2023
ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial
Pedro Giavina-Bianchi, Eric Cua, Karine Risso, et al.
Vaccine
|
May 11, 2010
Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccine
Eva Maria Pöllabauer, Sandor Fritsch, Borislava G Pavlova, et al.
Antibiotics & Chemotherapy (Northfield, Ill.)
|
February 19, 2014
6-Diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance. I. Biologic studies
G L COFFEY, J EHRLICH, M W FISHER, et al.
Page
of 28